Europe In Vitro Diagnostics Market to Reach USD 57 Billion by 2035 | Roche, Siemens Healthineers, bioMérieux, Qiagen Among Key Players

Europe's in vitro diagnostics market, currently valued at USD 32 billion in 2024, is forecast to climb to USD 34 billion in 2025 and reach USD 57 billion by 2035, advancing at a compound annual growth rate of 5.4% across the forecast period. The numbers reflect a region where diagnostic technology is no longer a supporting function of healthcare but a primary driver of clinical decision-making, investment flows, and public health strategy.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/europe-in-vitro-diagnostics-market/request-sample.html

The Europe in vitro diagnostics (IVD) industry covers the full spectrum of instruments, reagents, and software used to analyze biological samples, including blood, urine, tissue, and other body fluids, outside a living body. These tools are central to diagnosing conditions ranging from infectious diseases and cardiac disorders to cancer, diabetes, and autoimmune conditions. What makes IVD particularly critical right now is the convergence of several pressures on European healthcare systems: an aging population, a surging burden of chronic disease, and the urgent policy mandate for early, cost-effective diagnosis rather than late-stage, expensive intervention.

Europe has long attracted substantial industrial and institutional investment in medical innovation. The European Investment Bank's commitment of €20 million to Numares Health AG, a Regensburg-based diagnostics developer, illustrates the kind of capital that is flowing into this sector. Numares used that funding to develop the AXINON system, a fully automated IVD platform designed to improve diagnostic quality for chronic conditions such as heart disease, kidney disease, liver disease, and multiple sclerosis. At the policy level, the UK's National Health Service now operates more than 155 community diagnostic centers, with the government pledging to scale the volume of tests delivered through these centers from 7 million to 17 million by March 2025.

KEY GROWTH DRIVERS
Rising Incidence of Infectious and Chronic Diseases The World Health Organization reported more than 30,000 measles cases across 40 of its 53 European member states between January and October 2023, compared to just 941 cases in 2022, representing more than a 30-fold increase in a single year. This acceleration in infectious disease burden is sharpening demand for rapid, accurate molecular and immunodiagnostic testing throughout the region.

Expansion of Next-Generation Sequencing and Molecular Diagnostics Next-generation sequencing (NGS) technologies now enable rapid, whole-genome scanning for disease detection at the molecular level. QIAGEN received European IVDR certification in May 2024 for its Clinical Insight Interpret platform, the first NGS interpretation software to achieve IVDR certification for both hereditary disease and oncology applications. This milestone signals a broader shift toward precision diagnostics across European clinical workflows.

Government Investment in Diagnostic Infrastructure Public funding is actively expanding the physical and institutional capacity for diagnostic testing across Europe. Beyond the NHS community diagnostic center expansion in the UK, the EU's IVDR framework, despite its compliance complexity, is creating a long-term foundation for a more standardized and credible diagnostics market that attracts sustained industrial participation.

Shift Toward Personalized Medicine Pharmaceutical companies and hospital networks across Europe are integrating IVD techniques, including immunoassay, molecular diagnostics, and NGS, into treatment planning that is tailored to individual patient profiles at the molecular level. This shift increases the volume and variety of tests ordered per patient, directly expanding the addressable market for IVD manufacturers.

Growth in Point-of-Care and Home-Based Testing Several players are developing point-of-care testing systems that generate results in under 30 minutes. Sysmex launched the world's first point-of-care testing system for antimicrobial susceptibility detection in Europe in June 2023, reducing detection time to within 30 minutes. Home-based diagnostic kits represent a parallel growth channel, extending IVD access beyond clinical settings and broadening the end-user base significantly.

MARKET SEGMENTATION
The Europe in vitro diagnostics market breaks down across four primary dimensions: product type, technology, application area, and end user. By product, reagents hold the largest share of the market in 2024 and are expected to maintain that position through 2035, given their recurring-purchase nature and close integration with instrument platforms. Instruments account for the second-largest share, while other products, including software and consumables, contribute the remainder.

By technology, immunoassay leads all segments in 2024 and is projected to sustain dominant share across the forecast period. Clinical chemistry holds the second-largest position. By test type, laboratory testing commands the highest share today; however, point-of-care testing is forecast to grow at a faster CAGR through 2035, driven by the speed and convenience advantages it offers over centralized lab workflows. Hospitals are the largest end-user segment, a position that reflects their role as the primary site of complex diagnostic workloads across the continent.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/europe-in-vitro-diagnostics-market/request-quote.html

REGIONAL INSIGHTS
The report covers 11 key European countries: Austria, Belgium, France, Germany, Italy, the Netherlands, Poland, Spain, Switzerland, the UK, and the Rest of Europe. Germany and the UK stand out as the largest individual markets, underpinned by mature healthcare infrastructure, significant public health spending, and strong industrial ecosystems for medical device development.
France and Italy follow as substantial contributors to regional market volume.

Among the countries tracked, those in Eastern and Southern Europe, including Poland and Spain, are projected to grow at a faster rate relative to the more saturated Western markets. This reflects increasing healthcare modernization, rising diagnostic awareness, and growing government investment in health system capacity outside the traditional core markets. The regulatory harmonization created by the EU's IVDR framework, despite its short-term compliance burden, is expected to facilitate market standardization across all member states, reducing fragmentation and improving market access for manufacturers operating at scale.

COMPETITIVE LANDSCAPE
The leading companies profiled in this report include bioMérieux, Gold Standard Diagnostics, Grifols, Qiagen, Roche, Siemens Healthineers, and Werfen, among others.

The European IVD market is characterized by a mix of large multinational diagnostics groups and specialized mid-size players competing across technology platforms, therapeutic focus areas, and distribution reach. Roche and Siemens Healthineers maintain broad portfolios covering multiple technology categories, while companies like Qiagen have moved aggressively to secure regulatory certification for software-driven diagnostics. Strategic partnerships are an active battleground; Thermo Fisher Scientific's April 2023 agreement with ALPCO-GeneProof to co-market 37 CE-IVD molecular diagnostics assays is one recent example of larger players using alliances to rapidly expand their certified product portfolios. The compliance requirements of IVDR are reshaping competitive dynamics by raising the cost and complexity of market entry, which tends to benefit established players with dedicated regulatory affairs infrastructure.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/europe-in-vitro-diagnostics-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.